Q2 2025 Novo Nordisk A/S Earnings Call Transcript
Key Points
- Novo Nordisk AS (NVO) reported an 18% increase in sales and a 29% increase in operating profit for the first half of 2025.
- The company is serving almost 46 million patients with its diabetes and obesity treatments, marking an increase of over 3.5 million patients compared to the previous year.
- Obesity care sales increased by 58%, with international operations growing by 125%, driven by the strong performance of Wegovy.
- Novo Nordisk AS (NVO) has initiated several promising R&D projects, including the advancement of amycretin into Phase III clinical development for weight management.
- The company has entered an exclusive collaboration with Septerna to develop small molecules for treating obesity, Type-2 diabetes, and other cardiometabolic diseases.
- Novo Nordisk AS (NVO) has lowered its full-year sales outlook for 2025 due to lower growth expectations for Wegovy in the US obesity market and Ozempic in the US GLP-1 diabetes market.
- The company is facing challenges with unlawful mass compounding of semaglutide in the US, impacting Wegovy's market penetration.
- Sales growth in the US was affected by gross to net sales adjustments and a decline in volume, despite positive adjustments related to prior years.
- The company's gross margin decreased to 83.4% from 84.9% in 2024, mainly due to amortizations and depreciations related to Catalent and ongoing capacity expansions.
- Free cash flow decreased to DKK33.6 billion from DKK41.3 billion in the first six months of 2024, driven by increased capital expenditures.
Good day, and thank you for standing by. Welcome to the Q2 2025 Novo Nordisk Earnings Conference Call. (Operator Instructions). Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Jacob Rode, Head of Investor Relations. Please go ahead.
/-
Thank you. Hello, everyone, and welcome to this Novo Nordisk Earnings Call for the First Half Year of 2025. My name is Jacob Rode, and I'm the Head of Investor Relations at Novo Nordisk. And with me today, I have CEO of Novo Nordisk, Lars Fruergaard Jorgensen; Executive Vice President, Product and Portfolio Strategy, Ludovic Helfgott; Executive Vice President, US Operations, Dave Moore; Executive Vice President and Head of Development, Martin Holst Lange; Chief Financial Officer, Karsten Knudsen; and finally, Executive Vice President, International Operations as well as incoming CEO as of August 7, Mike Doustdar. All speakers will be available for the Q
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
